Condition (MeSH)
Heart Septal Defects, Atrial
ClinicalTrials.gov lists 192 trials for Heart Septal Defects, Atrial or a narrower condition beneath it. Abbott Medical Devices has the most among industry and government lead sponsors, with 12.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
80 of the 192 trials are tagged with Heart Septal Defects, Atrial itself; the rest are tagged with a narrower condition beneath it.
When did Heart Septal Defects, Atrial trials start? (30)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 16
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 15 |
| 2025 | 14 |
| 2024 | 14 |
| 2023 | 12 |
| 2022 | 16 |
| 2021 | 9 |
| 2020 | 13 |
| 2019 | 7 |
| 2018 | 9 |
| 2017 | 4 |
Showing 10 of 30 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 16 trials starting in 2026 and about 14 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 16 trials still running at the 2026-10-09 snapshot; registered median of 28 months across 82 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Heart Septal Defects, Atrial trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 1 |
| Phase 2 | 5 |
| Phase 2/3 | 2 |
| Phase 3 | 11 |
| Phase 4 | 11 |
| Not applicable | 79 |
| Observational | 78 |
| Expanded access | 2 |
How many Heart Septal Defects, Atrial trials are recruiting? (11)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 16 |
| Recruiting | 35 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 10 |
| Completed | 70 |
Showing 5 of 11 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Heart Septal Defects, Atrial trials? (8)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Abbott Medical Devices | 12 |
| Lifetech Scientific (Shenzhen) Co., Ltd. | 11 |
| W.L.Gore & Associates | 7 |
| China National Center for Cardiovascular Diseases | 4 |
| Carag AG | 3 |
Showing 5 of 8 sponsors.
Which drugs are being tested for Heart Septal Defects, Atrial? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| DEXMEDETOMIDINE | 3 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| EC Aspirin | 5 |
| No Interventions | 2 |
| Clopidogrel 75 | 2 |
| Sham Procedure | 2 |
| BLOOD SAMPLES | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Heart Septal Defects, Atrial trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Elective Surgery | 46 | 2 |
| Ischemic Stroke | 46 | 1 |
| Chest Pain | 35 | 2 |
| Migraine | 25 | 4 |
| Pneumonia | 20 | 5 |
Showing 5 of 10 adverse events.
Which publications cover Heart Septal Defects, Atrial? (138)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Interatrial Communications: Prevalence and Subtypes in 12,385 Newborns-a Copenhagen Baby Heart Study. | Pediatric cardiology | 2025 | Yes |
| The pathogenic role of calcitonin gene-related peptide and predictors of new-onset migraine and long-term outcomes after transcatheter atrial septal defect closure. | Headache | 2025 | Yes |
| Safety and efficacy of transcatheter correction of sinus venosus defect using 70-100mm-long partially covered Optimus-CVS® XXL stents compared with surgery: The OPTIVENOSUS study design. | Archives of cardiovascular diseases | 2025 | Yes |
| Electrocardiographic Characteristics in 438 Neonates with Atrial Septal Defects. | Pediatric cardiology | 2024 | Yes |
| Long-Term Results of the Atrial Septal Defect Occluder ASSURED Trial for Combined Pivotal/Continued Access Cohorts. | JACC. Cardiovascular interventions | 2024 | Yes |
Showing 5 of 138 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Interatrial communication | Point prevalence | 1-5 / 10 000 | Worldwide | Not stated | Exact |
| Interatrial communication | Point prevalence | 1-5 / 10 000 | Worldwide | Not stated | Exact |
| Interatrial communication | Point prevalence | 1-5 / 10 000 | Worldwide | Not stated | Unspecified |
| Interatrial communication | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Unspecified |
| Interatrial communication | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Interatrial communication | 1478 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Interatrial communication | 1478 | Exact | Orphadata Science knowledge files, Product 1 |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.